iv zanamivir looking good

I've never been able to find out if BTA will get royalties from this when it marketed. !!!


"There were no patterns or trends in adverse events and no new safety concerns were identified following administration of intravenous zanamivir.

Results from this study support the inclusion of subjects with renal impairment, with appropriate dose adjustment, in studies to evaluate intravenous zanamivir in the treatment of influenza."

http://aac.asm.org/content/early/2013/04/10/AAC.02330-12.short?rss=1